Business Description
Neurizon Therapeutics Ltd
SIC : 2834
ISIN : AU0000357261
Total Employee Number:
52Description
Neurizon Therapeutics Ltd is an Australian clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. Its lead candidate, NUZ-001 (S-monepantel), is being developed as a potential therapy for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions, based on the drug's proposed neuroprotective and anti-inflammatory mechanisms. The company's pipeline centers on repurposing and reformulating existing molecules for neurological indications, with an emphasis on progressing NUZ-001 through clinical trials. As a clinical-stage company, Neurizon does not yet generate product revenue; its funding comes primarily from equity capital raised from investors, along with any research grants or collaborations. Its activities span preclinical research, clinical development, and regulatory interactions, with operations based in Australia and a target market encompassing global patients with neurodegenerative disorders.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 7.84 | |||||
Equity-to-Asset | 0.54 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | -0.16 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -109.9 | |||||
3-Year EPS without NRI Growth Rate | -87.6 | |||||
3-Year FCF Growth Rate | -93.5 | |||||
3-Year Book Growth Rate | -37 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 73.8 | |||||
9-Day RSI | 71.19 | |||||
14-Day RSI | 68.06 | |||||
3-1 Month Momentum % | -25.71 | |||||
6-1 Month Momentum % | -42.86 | |||||
12-1 Month Momentum % | -64.38 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.16 | |||||
Quick Ratio | 2.16 | |||||
Cash Ratio | 1.16 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.8 | |||||
Shareholder Yield % | -17.86 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -134.98 | |||||
ROA % | -74.14 | |||||
ROIC % | -1450.1 | |||||
3-Year ROIIC % | 226.58 | |||||
ROC (Joel Greenblatt) % | -1497.9 | |||||
ROCE % | -125.53 | |||||
Moat Score | 2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 4.77 | |||||
Price-to-Tangible-Book | 3.95 | |||||
EV-to-EBIT | -5.75 | |||||
EV-to-EBITDA | -5.75 | |||||
EV-to-FCF | -3.57 | |||||
| Price-to-Net-Current-Asset-Value | 3.95 | |||||
Earnings Yield (Greenblatt) % | -17.41 | |||||
FCF Yield % | -23.67 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Neurizon Therapeutics Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.01 | ||
| Beta | 1.616 | ||
| 3-Year Sharpe Ratio | 0.33 | ||
| 3-Year Sortino Ratio | 0.58 | ||
| Volatility % | 91.06 | ||
| 14-Day RSI | 68.06 | ||
| 14-Day ATR (€) | 0.001586 | ||
| 20-Day SMA (€) | 0.030725 | ||
| 12-1 Month Momentum % | -64.38 | ||
| 52-Week Range (€) | 0.0235 - 0.0905 | ||
| Shares Outstanding (Mil) | 791.65 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Neurizon Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Neurizon Therapeutics Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| 0.05:1 Stock Split | 2015-10-30 | 0.02 (+0.00%) |
Show
Entries
Neurizon Therapeutics Ltd Frequently Asked Questions
What is Neurizon Therapeutics Ltd(FRA:ECQ0)'s stock price today?
The current price of FRA:ECQ0 is €0.04. The 52 week high of FRA:ECQ0 is €0.09 and 52 week low is €0.02.
When is next earnings date of Neurizon Therapeutics Ltd(FRA:ECQ0)?
The next earnings date of Neurizon Therapeutics Ltd(FRA:ECQ0) is .
Does Neurizon Therapeutics Ltd(FRA:ECQ0) pay dividends? If so, how much?
Neurizon Therapeutics Ltd(FRA:ECQ0) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers